NEW YORK, Jan. 15, 2015 /PRNewswire/ -- Vivus Inc. (NASDAQ: VVUS) is based out of Mountain View, California and is a biopharmaceutical company. The company's main focus is on the development and production of next-generation therapies and drugs for obesity, diabetes, sleep apnea and sexual health. Vivus has operations that expand globally, and are not limited to the US.
The company is expected to present an overview of their current position at the 33rd annual J.P. Morgan Healthcare Conference on January 15th, 2015, 9:00am PST. The current position in the industry as well as an update on the sales of their next-generation weight loss drug Qsyumia™ are expected to be addressed by management. Qsyumia™ including other weight-loss drugs developed in recent years has experienced weaker sales than initially anticipated. This was a result of high out-of-pocket costs coupled with inadequate insurance coverage.
For a more detailed research report with analyst comments, recommendation and price target on Vivus Inc. please follow the link below. There is no cost obligation to view the analyst brief.
Copy and paste to browser may be required.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.